JP3591166B2 - Anti-obesity agent - Google Patents

Anti-obesity agent Download PDF

Info

Publication number
JP3591166B2
JP3591166B2 JP30255696A JP30255696A JP3591166B2 JP 3591166 B2 JP3591166 B2 JP 3591166B2 JP 30255696 A JP30255696 A JP 30255696A JP 30255696 A JP30255696 A JP 30255696A JP 3591166 B2 JP3591166 B2 JP 3591166B2
Authority
JP
Japan
Prior art keywords
obesity
administration
body weight
obesity agent
lotus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP30255696A
Other languages
Japanese (ja)
Other versions
JPH10130159A (en
Inventor
実 杉浦
優美子 皆川
慎一郎 村岡
豊吉 吉澤
Original Assignee
正和薬品株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 正和薬品株式会社 filed Critical 正和薬品株式会社
Priority to JP30255696A priority Critical patent/JP3591166B2/en
Publication of JPH10130159A publication Critical patent/JPH10130159A/en
Application granted granted Critical
Publication of JP3591166B2 publication Critical patent/JP3591166B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Landscapes

  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)

Description

【0001】
【発明の属する技術分野】
本発明は、抗肥満剤に関する。更に詳しくは、植物の水抽出物を有効成分とする抗肥満剤に関する。
【0002】
【従来の技術】
食生活の欧米化や運動不足、精神的ストレスの増加などにより、脳血管性疾患や心疾患、肝臓病、糖尿病、高血圧などの成人病は増加の一途をたどっており、現在日本人の死亡原因の約6割を占めている。これら成人病患者に多くみられる太りすぎ、即ち肥満症は成人病の危険因子としてとらえられており、肥満を防ぐことがこれらの成人病を予防する上で重要な要素となっている。
【0003】
これ迄多くの抗肥満剤が臨床に供されているが、これらの薬物はその性質上重篤な副作用を避けることができず、また健康食品として上市されているものについては、それ程効果が期待できないのが現状である。
【0004】
【発明が解決しようとする課題】
本発明の目的は、副作用などの点で殆んど心配のない植物からの抽出物を有効成分とする抗肥満剤を提供することにある。
【0005】
【課題を解決するための手段】
かかる本発明の目的は、金線蓮全草の水抽出物を有効成分とする抗肥満剤によって達成される。
【0006】
【発明の実施の形態】
金線蓮(Anoectochilus formosanus)は、台湾において古くから珍重されているラン科の多年生薬用植物であって、葉はビロード状の濃い緑色をしており、その表面には金色の葉脈が走っている。また、台湾では薬王とも呼ばれており、滋養強壮、糖尿病、解熱、小児の発育不良、肺結核、肝臓病、腎臓病などに効果のある万能薬とされている。このように、実際に薬として用いられていることから、副作用の点では殆んど心配がないということができる。
【0007】
本発明においては、金線蓮全草の乾燥粉末の水抽出物、好ましくは熱水抽出物(薄赤紫色の粉末という状態で得られる)が用いられるが、メタノール、エタノール等の水溶性アルコールと水との混合溶媒も水抽出に用いることができる。金線蓮の水抽出物が抗高脂血症剤あるいは血糖値降下作用剤として有効であることは、先に本出願人によって見出されているが(特開平6−293,655号公報)、このものが抗肥満作用を有することは未だ知られていない。
【0008】
粉末として得られるこれらの抽出物の毒性は極めて低く、経口投与での急性毒性をウィスター(Wistar)系雄性ラットについて調べたところ、3000mg/kg(p.o.)でも死亡例はなかった。
【0009】
これらの抽出物は、医薬または食品の形態で提供される。医薬として用いる場合には、散剤、顆粒、錠剤、糖衣錠、カプセル、液剤などの形で提供され、また食品として用いられる場合には、ガム、キャンディ、ゼリー、錠菓、飲料などの形で提供される。医薬として用いられる場合には、経口投与、非経口投与、吸入、経直腸投与、局所投与などにより投与される。非経口投与には、皮下注射、静脈内投与、筋肉内投与、鼻孔内投与または注入などが含まれる。用いられる量は、一般に1回当り約10〜500mg/kg体重の範囲内であり、通常1日に1〜5回投与される。ただし、正確な用量は、患者の年令、体重、症状、投与経路などを考慮して、前記範囲内から決められる。
【0010】
【発明の効果】
金線蓮全草乾燥粉末の水抽出物、特に熱水抽出物は、アウロチオグルコース誘発による肥満モデルマウスの体重および脂肪組織重量を有意に抑制し、すぐれた抗肥満作用を発揮する。
【0011】
【実施例】
次に、実施例について本発明の効果を説明する。
【0012】
実施例
(アウロチオグルコース誘発肥満モデルマウスに対する抗肥満作用)
4週齢のICR雌性マウス(体重約20g)に、アウロチオグルコース(シグマ社製品)を体重1kg当り500mgの投与量で腹腔内投与し、肥満を誘発させた。この際、正常群には、生理食塩水を投与した。
【0013】
アウロチオグルコース投与2週間後に、健康なものだけを選び実験に用いた。実験は、アウロチオグルコース投与2週間後より、高脂肪食、即ち粉末飼料(オリエンタル酵母食品)にフルクトース20%およびコーンオイル10%をそれぞれ添加したものをマウスに与えた。
【0014】
対照群のマウスには、この高脂肪食のみを与え、実験群のマウスには、金線蓮全草乾燥粉末の熱水抽出物を1.0%または0.5%添加した高脂肪食を与え、実験開始から8週間後の体重および体重に対する子宮近傍の脂肪組織重量を測定した。得られた結果は、それぞれ図1および図2のグラフに示されている。
* P<0.01 vs. 正常群
# P<0.05 vs. 対照群
## P<0.01 vs. 対照群
【図面の簡単な説明】
【図1】肥満誘発8週間後の各実験区におけるマウスの体重で表わした抗肥満試験の結果を示すグラフである。
【図2】肥満誘発8週間後の各実験区におけるマウスの子宮近傍脂肪組織重量の体重に対する比(%)で表わした抗肥満試験の結果を示すグラフである。
[0001]
TECHNICAL FIELD OF THE INVENTION
The present invention relates to an anti-obesity agent. More specifically, the present invention relates to an anti-obesity agent containing a water extract of a plant as an active ingredient.
[0002]
[Prior art]
Due to the westernization of dietary habits, lack of exercise, and increased mental stress, adult illnesses such as cerebrovascular disease, heart disease, liver disease, diabetes, and high blood pressure are on the rise, and the cause of Japanese deaths is currently Account for about 60% of the total. Overweight, that is, obesity, which is often seen in these adult patients, is regarded as a risk factor for adult diseases, and preventing obesity is an important factor in preventing these adult diseases.
[0003]
Many anti-obesity drugs have been clinically used, but these drugs cannot avoid serious side effects due to their properties, and those drugs marketed as health foods are expected to be so effective. It is not possible at present.
[0004]
[Problems to be solved by the invention]
An object of the present invention is to provide an anti-obesity agent containing an extract from a plant which is hardly concerned about side effects and the like as an active ingredient.
[0005]
[Means for Solving the Problems]
The object of the present invention is attained by an antiobesity agent containing an aqueous extract of a whole lot of a golden wire lotus as an active ingredient.
[0006]
BEST MODE FOR CARRYING OUT THE INVENTION
Gold wire lotus (Anoectochilus formosanus) is a perennial medicinal plant of the orchid family, which has been prized for a long time in Taiwan, and its leaves have a velvety dark green color and golden veins run on its surface. . In Taiwan, it is also called Yakuo, a panacea that is effective against nutrition, tonicity, diabetes, fever, poor child growth, pulmonary tuberculosis, liver disease and kidney disease. Thus, since it is actually used as a drug, it can be said that there is almost no concern about side effects.
[0007]
In the present invention, an aqueous extract of a dry powder of a golden wire lotus plant, preferably a hot water extract (obtained in the form of a light reddish purple powder) is used, and a water-soluble alcohol such as methanol or ethanol is used. A mixed solvent with water can also be used for water extraction. It has been previously found by the present applicant that a water extract of a golden wire lotus is effective as an antihyperlipidemic agent or a hypoglycemic agent (JP-A-6-293655). However, it is not yet known that it has an anti-obesity effect.
[0008]
The toxicity of these extracts obtained as powders was extremely low, and acute toxicity by oral administration was examined in male Wistar rats, and no death occurred at 3000 mg / kg (po).
[0009]
These extracts are provided in pharmaceutical or food form. When used as a medicine, it is provided in the form of powders, granules, tablets, dragees, capsules, liquids, and the like, and when used as a food, it is provided in the form of gum, candy, jelly, tablet confections, beverages, etc. You. When used as a medicine, it is administered by oral administration, parenteral administration, inhalation, rectal administration, topical administration and the like. Parenteral administration includes subcutaneous injection, intravenous administration, intramuscular administration, nasal administration or infusion. The amounts used will generally be within the range of about 10-500 mg / kg body weight per dose and will usually be administered 1-5 times daily. However, the exact dose is determined from the above range in consideration of the patient's age, body weight, symptoms, administration route and the like.
[0010]
【The invention's effect】
The water extract, especially the hot water extract, of the dried powder of the golden wire lotus whole plant significantly suppresses the aurothioglucose-induced obesity model mouse body weight and adipose tissue weight, and exhibits an excellent anti-obesity effect.
[0011]
【Example】
Next, the effects of the present invention will be described with reference to examples.
[0012]
Example (Anti-obesity effect on aurothioglucose-induced obesity model mouse)
Aurothioglucose (manufactured by Sigma) was intraperitoneally administered to 4-week-old ICR female mice (body weight: about 20 g) at a dose of 500 mg / kg body weight to induce obesity. At this time, physiological saline was administered to the normal group.
[0013]
Two weeks after administration of aurothioglucose, only healthy ones were selected and used in the experiment. Two weeks after the administration of aurothioglucose, mice were fed a high-fat diet, that is, a powdered feed (Oriental yeast food) supplemented with 20% fructose and 10% corn oil, respectively.
[0014]
The mice in the control group were fed only this high-fat diet, and the mice in the experimental group were fed a high-fat diet to which 1.0% or 0.5% of a hot water extract of the dried powder of golden wire lotus was added. Eight weeks after the start of the experiment, the body weight and the adipose tissue weight near the uterus with respect to the body weight were measured. The results obtained are shown in the graphs of FIGS. 1 and 2, respectively.
* P <0.01 vs. Normal group #P <0.05 vs. Control group ## P <0.01 vs. Control group [Brief description of drawings]
FIG. 1 is a graph showing the results of an anti-obesity test expressed in terms of mouse body weight in each experimental group 8 weeks after the induction of obesity.
FIG. 2 is a graph showing the results of an anti-obesity test expressed as a ratio (%) of the weight of the adipose tissue in the vicinity of the uterus to the body weight of each mouse in each experimental group 8 weeks after the induction of obesity.

Claims (1)

金線蓮全草の水抽出物を有効成分とする抗肥満剤。An anti-obesity agent containing an aqueous extract of the whole lotus of the golden wire lotus as an active ingredient.
JP30255696A 1996-10-28 1996-10-28 Anti-obesity agent Expired - Fee Related JP3591166B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP30255696A JP3591166B2 (en) 1996-10-28 1996-10-28 Anti-obesity agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP30255696A JP3591166B2 (en) 1996-10-28 1996-10-28 Anti-obesity agent

Publications (2)

Publication Number Publication Date
JPH10130159A JPH10130159A (en) 1998-05-19
JP3591166B2 true JP3591166B2 (en) 2004-11-17

Family

ID=17910408

Family Applications (1)

Application Number Title Priority Date Filing Date
JP30255696A Expired - Fee Related JP3591166B2 (en) 1996-10-28 1996-10-28 Anti-obesity agent

Country Status (1)

Country Link
JP (1) JP3591166B2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI379688B (en) * 2009-10-05 2012-12-21 Univ China Medical Anoectochilus spp. polysaccharide extracts and pharmaceutical compositions for stimulating growth of advantageous bacteria, stimulating release of granulocyte colony-stimulating factor, modulating t helper cell type i, and/or modulating t helper cell typ
TW201515649A (en) * 2013-10-24 2015-05-01 Univ Tunghai Anoectochilus spp. fermentation product and its manufacturing method and application

Also Published As

Publication number Publication date
JPH10130159A (en) 1998-05-19

Similar Documents

Publication Publication Date Title
KR100842193B1 (en) Compositions for preventing or ameliorating multiple risk factor syndromes
JP6271571B2 (en) Composition for maintaining intestinal microbiota equilibrium, process for producing the composition, and use of the composition
CN101224282B (en) Medicine compounds for treating infantile anorexia and preparing method thereof
CN102028900B (en) Traditional Chinese medicine for treating metabolic syndrome and preparation method thereof
AU2007245501B2 (en) Use of saffron and/or safranal and/or crocin and/or picrocrocin and/or derivatives thereof as a sateity agent for treatment of obesity
CN102271698B (en) Pharmaceutical composition and use for preparing medicament thereof
TW201345539A (en) Use of antrodia camphorata for treating diseases
CN115364170B (en) Sugar metabolism regulator and preparation method and application thereof
GB2503628A (en) Pharmaceutical compostion for controlling blood sugar, blood lipid and body weight
CN113425817A (en) Traditional Chinese medicine composition for strengthening spleen and stomach and promoting digestion and removing food retention as well as preparation method and application thereof
CN103386078B (en) A kind of Chinese medicine composition is preparing the application in treating colon cancer drug
JP3591166B2 (en) Anti-obesity agent
JP6369931B2 (en) Anti-obesity agent
CN107213391A (en) One kind has strengthening spleen and nourishing stomach, and help digestion pharmaceutical composition of tune fat and preparation method thereof
CN1069203C (en) Drug for curing diabetes
CN109999044B (en) Composition containing withaferin A and application thereof
CN1985877A (en) Astragalus extract and its medicine use
KR100827350B1 (en) Herbal medicine composition for descending blood sugar
WO2019218537A1 (en) Chitosan composition and preparation method therefor
CN103301380A (en) Liver-soothing and qi-regulating traditional Chinese medicinal composition and preparation method thereof
WO2018188548A1 (en) Traditional chinese medicine composition with hypoglycemic effect
CN114748567B (en) Hypoglycemic composition containing antrodia camphorata and preparation method and application thereof
KR20190110204A (en) Kyung-ok-go having high acceptability and anti-diabetes activity adding the silk of zea mays and pumpkin
CN100411670C (en) Medicine for treating tumor in upper digestive tract and its preparing method
JP2016165282A (en) Composition for treating obesity and diabetes and for increasing muscle mass and improving capacity for exercise, comprising extracts of piper retrofractum vahl. fruits as active ingredients

Legal Events

Date Code Title Description
TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20040803

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20040816

R150 Certificate of patent (=grant) or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080903

Year of fee payment: 4

LAPS Cancellation because of no payment of annual fees